Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme
Class IITerminatedD-0154-2018

Drug recall · January 17, 2018

Viokace recall

Why: Subpotent Drug: One lot of Viokace is being recalled since product stability testing results did not meet the specifications for enzyme profile.

Class II: could cause temporary or reversible health problems; serious harm is remote.

The recall

Product

Viokace (pancrelipase) tablets, 20,880 USP units, 100-count bottle, Rx only, Distributed by; Allergan USA Inc., Irvine, CA 92612, Manufactured in Canada, NDC 58914-117-10

Lots / codes

Lot #: 160741A, Exp 02/18

Quantity
12,699 bottles
Company
Allergan, Madison, NJ
Distribution
U.S.A. nationwide
Initiated
December 4, 2017 · Voluntary: Firm initiated
Classified
January 5, 2018
Reported
January 17, 2018
Ended
June 20, 2019
How notified
Letter

The drug: prices, other makers, shortages

If you have this product

  1. Check the lot number on your package against the lots above. Only those lots are recalled.
  2. Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
  3. Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
  4. Return or dispose of recalled product as the company or your pharmacy advises.

Questions about this recall

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Watch Viokace

One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.